Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab-based comprehensive treatment for pancreatic cancer
ChiCTR2300078481Phase 4Recruiting
- Sponsor
- Anhui Cancer Hospital
- Start
- Dec 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of nimotuzumab in pancreatic cancer (PC) and pancreatic adenocarcinoma (PDAC) (3 cohorts), sponsored by Anhui Cancer Hospital. Primary endpoint: Overall survival. Started Dec 2023; status: recruiting.
02
Drugs
nimotuzumab
03
Conditions
pancreatic cancer (PC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ChiCTR2300078481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300078481.